These meteors will streak across night skies this July. When to see them in Michigan
Look up in the night sky later this month to catch a glimpse of the alpha Capricornids and Southern Delta Aquariids passing over Michigan.
Here's what to know.
When do July 2025's meteor showers peak?
The alpha Capricornids and Southern Delta Aquariids are set to peak between July 29-30, per the American Meteor Society.
What is a meteor shower?
A meteor shower occurs when the Earth passes through a trail of debris left behind by a comet or less commonly an asteroid, according to NASA. The celestial events happen annually or at other intervals, NASA says.
What are the alpha Capricornids?
The alpha Capricornids is an annual meteor shower with low activity, typically producing about five slow-moving meteors per hour, per the American Meteor Society.
The meteor shower began July 12 and will be active through Aug. 12, the society says.
What are the Southern Delta Aquariids?
The Southern Delta Aquariids is an annual meteor shower with faint meteors, typically producing about seven to eight meteors per hour, according to NASA.
This meteor shower started July 18 and will run until Aug. 12, per the American Meteor Society.
Where can you view the meteor showers in Michigan?
Keep an eye on the weather forecast as the peak nears, as clear skies are essential for viewing chances. Michigan is home to six dark sky state parks, three international dark sky parks and an international dark sky sanctuary.
The Alpena area has three Dark Sky Preserves: Rockport State Recreation Area, Thompson's Harbor State Park and Negwegon State Park.
In Mackinaw City, Headlands International Dark Sky Park.
In Empire, Sleeping Bear Dunes National Lakeshore.
In Munising, Pictured Rocks National Lakeshore.
In Paradise, the Great Lakes Museum and Whitefish Point Light Station and Tahquamenon Falls State Park.
In Port Austin, Port Crescent State Park.
In Clayton, Lake Hudson Recreation Area.
In Carp Lake, Wilderness State Park.
Keweenaw Dark Sky Park in Keweenaw County and Dr. T.K. Lawless Park in Cass County are international spots. And, finally, the Beaver Island State Wildlife Research Area is an international sanctuary.
When is the next meteor shower?
The Perseids will peak Aug. 12-13.
Contact Jenna Prestininzi: jprestininzi@freepress.com.
This article originally appeared on Detroit Free Press: Meteors Alpha Capriconids, Southern Delta Aquariids will peak in late July
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
5 minutes ago
- Miami Herald
Blocks all stacked for NASA's future Artemis tower at KSC
There's still more than a year's worth of work to do on NASA's future Artemis launch tower at Kennedy Space Center, but all of the big pieces have been put in place. The last of seven modular steel blocks that make up the bulk of the tower's height was put into place on July 2 by the tower's contractor Bechtel. The block called Mod 10 brings it to 377 feet tall from the base structure. "This achievement underscores our ongoing partnership with NASA and local unions, and the team's steady progress toward safe delivery of this critical infrastructure," the company said in an emailed statement. Progress has been tracked on the company's website with the latest addition dubbed "Reaching the Top." Mod 4 was the first of the seven blocks put in place on Jan. 3, growing the structure 272 feet in less than six months. Mod 10 will support the Crew Access Arm for ML-2, which is among the parts that have yet to be assembled before the company's deadline of November 2026 for delivery to NASA. ML-2 is designed for use on a larger version of NASA's Space Launch System rocket, which won't fly until at least the Artemis IV mission on NASA's roadmap in late 2028. The first three Artemis missions have or will use the ML-1, which was converted from use from NASA's defunct Constellation program. Artemis I was the first launch of SLS, an uncrewed test flight that sent Orion out to the moon and back. Artemis II will be the first crewed flight of Orion, looking to send four astronauts on a trip around the moon without landing no later than April 2026. Artemis III looks to return humans to the moon for the first time since the end of the Apollo program in 1972. That mission, which is reliant on the completion of SpaceX's in-development Starship as a human landing system as well as new spacesuits from Axiom Space, is targeting launch by summer 2027. Whether or not ML-2 would ever be used was in question as President Donald Trump's proposed budget for fiscal year 2026 sought to end the SLS rocket program as well as the Orion spacecraft, Gateway lunar space station and NASA's Exploration Ground Systems team based at KSC after the flight of Artemis III. But Congress, led by an effort from Sen. Ted Cruz, was able add more than $10 billion in this year's "Big, Beautiful Bill" to save SLS for both the fourth and fifth launches of Artemis as well as set aside money for Orion and Gateway. Both versions of the Senate and House budget bills for 2026, moreover, look to keep funding for Artemis' existing programs in place. Congress is the ultimate decider of what the federal budget will look like, although without an agreement, it's possible NASA will simply continue with funding based on current levels with continuing resolutions. Still, with funds already set aside, work continued in earnest to get ML-2 ready for the fourth Artemis flight. It's supposed to fly the first part of the Gateway station, and would use the larger version of SLS called the Block 1B that has more payload capacity. It too would feature a rendezvous and moon landing with Starship. The Artemis V mission is supposed to be the first flight to use Blue Origin's Blue Moon lander instead of Starship. NASA will still need to perform about a year's worth of tests and added work after Bechtel hands it off in 2026. The ML2 project, which was initially a $383 million contract awarded in 2019, had an original delivery date of 2023. A NASA Office of Inspector General audit released in August 2024 said the costs had already nearly tripled to more than $1 billion with the delivery date pushed into late 2026. It's part of the growing costs and delays associated with all facets of the Artemis program. In 2023, the OIG said by the time Artemis III flies, the program will have topped $93 billion in costs since it was originally announced in 2012. -------------- Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.
Medscape
5 minutes ago
- Medscape
ADA 2025: Progress in Managing Type 1 Diabetes
This transcript has been edited for clarity. The one study that my patients with type 1 diabetes asked me about from the American Diabetes Association meetings was the Vertex study, where stem cell-derived islet cells were given to individuals with type 1 diabetes and followed for a year. They reported on 12 participants, and basically, these little islet cells worked. The problem, of course — and the reason I had to disappoint my patients — is that it didn't work without immunosuppression. These patients required immunosuppression, but in the setting of immunosuppression, the little new islet cells worked. We saw an increase in C-peptide production. Most patients got off of insulin. The patients had no further episodes of severe hypoglycemia, and the patients really were cured, in essence, of their type 1 diabetes — at least the small number of people followed for a year. The downside, of course, is the immunosuppression, and that's where the side effects occurred. I think this was really interesting because it's certainly proof of concept that we can take stem cells, make islet cells, and infuse them into people and have them work. We just have to figure out a way to do it without immunosuppression. The next study that my patients and I found interesting came from the Barbara Davis Center and was done by Dr Halis Akturk and his colleagues. It was looking at the use of semaglutide 1 mg as an adjunct to insulin in people with type 1 diabetes and obesity who are on automated insulin delivery systems. Now, in full disclosure, I do this all the time in my patients who are overweight or obese who wish to try combination therapy off-label with semaglutide, but this is the first randomized controlled trial to show the benefit. This was called the ADJUST-T1D trial. It was a double-blind study. This was a 26-week placebo-controlled study, and they enrolled 72 individuals with type 1 diabetes from four US clinics. They were randomized 1:1 to semaglutide or placebo once weekly while they continued on their usual automated insulin delivery systems. The insulin adjustments were guided by the investigators, along with the patients, looking at time in range, time below range, and other continuous glucose monitoring parameters. These individuals had to have a BMI ≥ 30 and an A1c between 7% and 10% coming into the study. These are fairly typical individuals with type 1 diabetes who are overweight, and they had a baseline A1c of 7.7%. The primary outcome was a composite one, looking at how many people achieved a time in range of > 70%, time below range of < 4%, and ≥ 5% weight loss. This composite endpoint was met in 36% of the participants in the semaglutide group, and this was highly significant compared to the placebo group. In terms of secondary outcomes, there was a reduction in A1c by 0.7% in the semaglutide group compared to 0.3% in the placebo group. Time in range improved. People lost, on average, 18 lb, and there was a reduction in total daily insulin dose. There was no diabetic ketoacidosis, but there were two episodes of severe hypoglycemia in each group. This was really proof of concept, which I think all of us who treat many people with type 1 diabetes and have been using incretin therapy have shown to be beneficial. I think the things we still need to watch for is obviously weight loss that's too fast because I don't think this is good for anybody, and the fact that people will need less insulin, so the insulin doses need to be reduced as people use these agents. Patients on these automated insulin delivery systems tend to do pretty well. I'm often adjusting the carb ratio and maybe the sensitivity depending on the pump, but I found this to be a pretty safe and effective way to do it. I think you just start lower, you go up slowly, and you make sure patients are tolerating the medication. I think patients really see benefit. What's not measured here are the nonglycemic benefits that we know are part of the use of incretin therapies, which I think is important. In my own clinic, I looked at outcomes at 2 years retrospectively, and people had still maintained the weight loss but some of the glycemic improvements waned over time. I think that just goes to show the difficulty of managing people with type 1 diabetes. I think this helps, and I think this was a really good trial. I'm very grateful to the investigators for doing this study. These two presentations highlight some of the progress in how we're thinking about dealing with type 1 diabetes. First, the notion of hopefully, someday having a cure that helps people with type 1 diabetes, having new beta cells that actually work. The second is using some of the drugs that we're now familiar with in terms of their benefits to people with type 2 diabetes in people with type 1 diabetes, and showing that it can be done safely and effectively. This has been Dr Anne Peters for Medscape. Thank you.
New York Times
6 minutes ago
- New York Times
The Quest for a Lost Chinese Typewriter
In 2010, Tom Mullaney found himself way out in the suburbs of London. A woman there wanted to show him a Chinese typewriter. She was going to be renovating her house soon, she told him, and it needed a new home. Dr. Mullaney, a professor of Chinese history at Stanford University, had spent years searching the globe for Chinese typewriters, wondrous machines capable of printing thousands of Chinese characters while remaining small enough to keep on a desk. The typewriter, 50 pounds of metal frame and levers, was one of a dying breed. If he didn't save it, would it wind up on a scrapheap? It went into a suitcase and he took it back to California, where it joined a growing collection of Asian-language typing devices that he'd hunted down. But there was one typewriter that Dr. Mullaney had little hope of ever finding: the MingKwai. Made by an eccentric Chinese linguist turned inventor living in Manhattan, the machine had mechanics that were a precursor to the systems almost everyone now uses to type in Chinese. Only one — the prototype — was ever made. 'It was the one machine,' he said recently, 'which despite all my cold-calling, all my stalking, was absolutely, 100 percent, definitely gone.' Want all of The Times? Subscribe.
